Epidemiological Study on Community Acquired Pneumonia (CAPNETZ)

April 29, 2026 updated by: Capnetz Stiftung
The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The CAPNETZ study is a prospective, multicenter observational study investigating community-acquired pneumonia (CAP). Patients are recruited from outpatient and inpatient settings at hospitals and from primary care physicians (primarily specialists) and are followed for a period of six months. All CAP patients who meet the inclusion and exclusion criteria, consent to participate, and in whom the presence of a newly developed, community-acquired pneumonia can be verified are invited to participate. The baseline examination includes a detailed medical history, medication history, and a physical examination to record clinical and vital signs. In addition, the results of routine clinical imaging are documented, and biosamples (blood, urine, and respiratory specimens) are collected for clinical chemistry and microbiological analysis. Further in-person visits to document the course of the disease and treatment, including the collection of additional blood samples, take place 3 and 7 days after study enrollment. Twenty-eight days after enrollment, the patient's health status, treatment course, and complications are assessed by telephone. Finally, after 180 days, a telephone survey is conducted to determine the patient's whereabouts and survival status. Apart from the collection of biomaterials, no interventions are required or planned; physicians treat their patients as they normally would.

Study Type

Observational

Enrollment (Estimated)

20000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Germany
      • Hanover, Germany, 30625
        • Recruiting
        • Medical School Hannover
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients with pneumonia

Description

Inclusion Criteria:

  • age ≥ 18
  • infiltrate on chest X-ray
  • further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever

Exclusion Criteria:

  • Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia
  • Newly diagnosed, active pulmonary tuberculosis within the last 2 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patients with pneumonia
Other: Cohort Study
patients with CAP and HIV
immunosuppressed patients with CAP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
diagnosis
Time Frame: 2 weeks

Assessment of diagnosis:

Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.
2 weeks
therapy
Time Frame: 2 weeks

Assessment of therapy:

Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.
2 weeks
hospitalization
Time Frame: 2 weeks

Assessment of hospitalization:

Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Capnetz Stiftung

Collaborators

Deutsches Zentrum für Lungenforschung e. V.

Investigators

  • Study Chair: Gernot G. U. Rohde, Prof. Dr., University Hospital Giessen and Marburg
  • Study Chair: Mathias W. R. Pletz, Prof. Dr., University Hospital Jena
  • Study Chair: Jan Rupp, Prof. Dr., University Hospital Schleswig-Holstein
  • Study Chair: Martin Witzenrath, Prof. Dr., Charite - Universitaetsmedizin Berlin
  • Study Chair: Jessica Rademacher, Prof. Dr., Medical School Hannover
  • Study Chair: Grit Barten-Neiner, Capnetz Stiftung

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2002

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

June 1, 2028

Study Registration Dates

First Submitted

January 24, 2014

First Submitted That Met QC Criteria

May 12, 2014

First Posted (Estimated)

May 15, 2014

Study Record Updates

Last Update Posted (Actual)

May 5, 2026

Last Update Submitted That Met QC Criteria

April 29, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • U1111-1147-8393

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All individual non-personal data and biomaterials collected as part of the study are available for use. This requires a formal request that describes a specific research project and specifies the data needed. Applications have to be submitted on https://capnetz.de/en/project-application/ .

Upon approval by the Executive Board, the relevant data and biomaterials will be provided.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Community Acquired Pneumonia

Clinical Trials on Cohort Study

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe